Drug-Carbamazepine (Tegretol XR)

Phase 2Small molecule

WWashington University School of Medicine

Drug-Carbamazepine (Tegretol XR) is one of 17 small molecule programs targeting Alpha-1 Antitrypsin Deficiency. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alpha-1 Antitrypsin DeficiencyActive, not recruiting

Alpha-1 Antitrypsin DeficiencyPhase 2

Active, not recruiting

Competition

Competitive Landscape

31 competitors in Alpha-1 Antitrypsin Deficiency

#DrugCompanyPhaseTrials

Bayer Aspirin

Bayer

Phase 2

1 2

Benadryl

PParkedale

Phase 1

1 3

SAR447537

Sanofi

Phase 2

1 4

Zofran

Novartis

Preclinical

1 5

RG6026

Roche

Phase 1

—6

Alvelestat

UUniversity of Alabama at Birmingham

Phase 2

1 7

Biological NTLA-2002

Intellia Therapeutics

Phase 2

1 8

Duragesic

CCephalon

Preclinical

1 9

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 10

Tylenol

KKenvue Brands

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Alpha-1 Antitrypsin Deficiency1 trial

Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency

Terminated·WWashington University School of Medicine·Phase 2·NCT01379469·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Drug-Carbamazepine (Tegretol XR). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Drug-Carbamazepine (Tegretol XR) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Drug-Carbamazepine (Tegretol XR). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Washington University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: WWashington University School of Medicine

Drug-Carbamazepine (Tegretol XR)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Alpha-1 Antitrypsin Deficiency1 trial

References

Drug Info

Quick Facts

Related News